BRPI0413745A - horário mde dosagem para agentes anticancerìgenos erbb2 - Google Patents

horário mde dosagem para agentes anticancerìgenos erbb2

Info

Publication number
BRPI0413745A
BRPI0413745A BRPI0413745-0A BRPI0413745A BRPI0413745A BR PI0413745 A BRPI0413745 A BR PI0413745A BR PI0413745 A BRPI0413745 A BR PI0413745A BR PI0413745 A BRPI0413745 A BR PI0413745A
Authority
BR
Brazil
Prior art keywords
erbb2
mammal
relates
anticancer agents
dosing schedule
Prior art date
Application number
BRPI0413745-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Samit Kumar Bhattacharya
Richard Damian Connell
James Dale Moyer
Jitesh Pranlal Jani
Dennis Alan Roe
Stefanus Johannes Steyn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0413745A publication Critical patent/BRPI0413745A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0413745-0A 2003-08-18 2004-08-06 horário mde dosagem para agentes anticancerìgenos erbb2 BRPI0413745A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18
PCT/IB2004/002580 WO2005016347A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Publications (1)

Publication Number Publication Date
BRPI0413745A true BRPI0413745A (pt) 2006-10-24

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413745-0A BRPI0413745A (pt) 2003-08-18 2004-08-06 horário mde dosagem para agentes anticancerìgenos erbb2

Country Status (18)

Country Link
US (1) US20050119288A1 (cg-RX-API-DMAC7.html)
EP (1) EP1658080A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007502807A (cg-RX-API-DMAC7.html)
KR (2) KR20060037447A (cg-RX-API-DMAC7.html)
CN (1) CN1838959A (cg-RX-API-DMAC7.html)
AR (1) AR045268A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004264726A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0413745A (cg-RX-API-DMAC7.html)
CA (1) CA2536140A1 (cg-RX-API-DMAC7.html)
CO (1) CO5670356A2 (cg-RX-API-DMAC7.html)
IL (1) IL173127A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06001989A (cg-RX-API-DMAC7.html)
NO (1) NO20061252L (cg-RX-API-DMAC7.html)
RU (1) RU2328287C2 (cg-RX-API-DMAC7.html)
SG (1) SG135193A1 (cg-RX-API-DMAC7.html)
TW (1) TW200522966A (cg-RX-API-DMAC7.html)
WO (1) WO2005016347A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200600517B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064383A2 (en) 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
RU2350605C2 (ru) * 2003-08-14 2009-03-27 Эррей Байофарма Инк. Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
DK1667992T3 (da) 2003-09-19 2007-04-30 Astrazeneca Ab Quinazolinderivater
RS52119B (sr) * 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-fenilamino-hinazolin-6-il-amidi
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
JP2008542354A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
KR20080027253A (ko) * 2005-06-16 2008-03-26 미리어드 제네틱스, 인크. 약제학적 조성물 및 이의 용도
JP2009502960A (ja) * 2005-07-27 2009-01-29 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ
US8945573B2 (en) * 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
JP5709354B2 (ja) * 2005-11-14 2015-04-30 アリアド・ファーマシューティカルズ・インコーポレイテッド ｍＴＯＲ阻害剤投与によるがん患者の治療
WO2007059257A2 (en) 2005-11-15 2007-05-24 Array Biopharma Inc. N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
JP2009532358A (ja) * 2006-03-31 2009-09-10 マサチューセッツ・インスティテュート・オブ・テクノロジー 突然変異型ｅｇｆ受容体を発現する腫瘍の治療
EP2004165A2 (en) * 2006-04-05 2008-12-24 Novartis Pharma AG Synergistic combinations of anticancer agents for treating cancer
US20080161335A1 (en) 2006-11-14 2008-07-03 Vladyka Ronald S Oral formulations
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
CA2720983A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
NZ580869A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Methods for treating cancer
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
JP2010523696A (ja) * 2007-04-10 2010-07-15 ミリアド ファーマシューティカルズ， インコーポレイテッド 脳腫瘍を治療する方法
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US8252805B2 (en) * 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
HK1203378A1 (en) 2011-11-23 2015-10-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
SG11201606193RA (en) 2014-01-31 2016-08-30 Toppan Printing Co Ltd Biomolecule analysis kit and biomolecule analysis method
US11160871B2 (en) 2015-10-28 2021-11-02 Tarveda Therapeutics, Inc. SSTR-targeted conjugates and particles and formulations thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1996030347A1 (en) * 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
OA12291A (en) * 2000-06-22 2004-03-18 Pfizer Prod Inc Substituted bicyclic derivatives for the treatmentof abnormal cell growth.
MXPA04004107A (es) * 2001-12-12 2004-07-23 Pfizer Prod Inc Moleculas pequenas para el tratamiento del crecimiento celular anormal.
PL370858A1 (en) * 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
EP1567506A4 (en) * 2002-11-20 2007-06-20 Array Biopharma Inc CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
PL377686A1 (pl) * 2002-12-18 2006-02-06 Pfizer Products Inc. Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek

Also Published As

Publication number Publication date
JP2007502807A (ja) 2007-02-15
SG135193A1 (en) 2007-09-28
US20050119288A1 (en) 2005-06-02
EP1658080A1 (en) 2006-05-24
CO5670356A2 (es) 2006-08-31
KR20060037447A (ko) 2006-05-03
KR20080014144A (ko) 2008-02-13
AU2004264726A1 (en) 2005-02-24
RU2328287C2 (ru) 2008-07-10
WO2005016347A1 (en) 2005-02-24
AR045268A1 (es) 2005-10-19
TW200522966A (en) 2005-07-16
MXPA06001989A (es) 2006-05-17
RU2006102125A (ru) 2007-09-27
IL173127A0 (en) 2006-06-11
CN1838959A (zh) 2006-09-27
NO20061252L (no) 2006-05-16
ZA200600517B (en) 2007-02-28
CA2536140A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
BRPI0413745A (pt) horário mde dosagem para agentes anticancerìgenos erbb2
DIONNE et al. Suppression of postoperative pain by preoperative administration of ibuprofen in comparison to placebo, acetaminophen, and acetaminophen plus codeine
Argyriou et al. A review on oxaliplatin-induced peripheral nerve damage
Kosharskyy et al. Intravenous infusions in chronic pain management
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
BRPI0413580A (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer em um mamìfero em necessidade de tal tratamento, para modular a formação do fuso mitótico e para inibir a cinesina mitótica ksp
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
IL128723A0 (en) Pharmaceutical compositions containing rar antagonists and rxr agonists
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
Mansouri et al. Ellagic acid enhances the antinociceptive action of venlafaxine in mouse acetic acid-induced pain: An isobolographic analysis
BR0014166A (pt) Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
BRPI0517104A (pt) tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BRPI0411608A (pt) derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo
JP2016507493A5 (cg-RX-API-DMAC7.html)
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
Jia et al. CD73 regulates hepatic stellate cells activation and proliferation through Wnt/β-catenin signaling pathway
BRPI0607536A2 (pt) tratamento de dor
Marri Adjuvant agents in regional anaesthesia
Vallejo et al. Preemptive analgesia with bupivacaine for segmental mastectomy

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.